Chi­nese biotech start­up adds $315M to the bank af­ter bring­ing 5 Take­da drugs to its fold

More than two years af­ter ar­riv­ing on the Chi­na bio­phar­ma scene with a $322 mil­lion deal for five of Take­da’s drugs, Has­ten Bio­phar­ma has land­ed $315 mil­lion to fu­el fu­ture ac­qui­si­tions.

CBC Group, the in­vest­ment firm that helped put the com­pa­ny to­geth­er, is once again head­lin­ing the round, joined by Abu Dhabi sov­er­eign wealth fund Mubadala in co-lead­ing a line­up of in­sti­tu­tion­al in­vestors.

Has­ten is based in Hefei, a five-hour dri­ve to the east from Chi­na’s biotech hub in Shang­hai, and ac­cord­ing to its web­site, has built a team of more than 700 peo­ple since launch­ing in 2020.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN